These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6152317)

  • 21. Differential effects of opiate agonists-antagonists on morphine-induced hyperexcitability and analgesia in mice.
    Filibeck U; Castellano C; Oliverio A
    Psychopharmacology (Berl); 1981; 73(2):134-6. PubMed ID: 6785803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of the formalin test in evaluating analgesics.
    Cowan A; Porreca F; Wheeler H
    NIDA Res Monogr; 1989; 95():116-22. PubMed ID: 2577032
    [No Abstract]   [Full Text] [Related]  

  • 23. A comparison of the antinociceptive and behavioral effects of intrathecally administered opiates, alpha-2-adrenergic agonists, and local anesthetics in mice and rats.
    Ossipov MH; Suarez LJ; Spaulding TC
    Anesth Analg; 1988 Jul; 67(7):616-24. PubMed ID: 2898220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mixed agonist-antagonist opiates and physical dependence.
    Jacob JJ; Michaud GM; Tremblay EC
    Br J Clin Pharmacol; 1979; 7 Suppl 3(Suppl 3):291S-296S. PubMed ID: 572694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Action of opioid agonist-antagonist drugs on the pupil and nociceptive responses in mice.
    Stav A; Rabinowitz R; Korczyn AD
    J Anesth; 1992 Oct; 6(4):439-45. PubMed ID: 15278517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nalbuphine coadministered with morphine prevents tolerance and dependence.
    Lee SC; Wang JJ; Ho ST; Tao PL
    Anesth Analg; 1997 Apr; 84(4):810-5. PubMed ID: 9085963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolerance to the analgesic effect of buprenorphine, butorphanol, nalbuphine, and cyclorphan, and cross-tolerance to morphine.
    Gringauz M; Rabinowitz R; Stav A; Korczyn AD
    J Anesth; 2001; 15(4):204-9. PubMed ID: 14569437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tolerance and cross-tolerance to the rate-suppressing effects of opioids in butorphanol-treated rats: influence of maintenance dose and relative efficacy at the mu receptor.
    Smith MA; Picker MJ
    Psychopharmacology (Berl); 1998 Nov; 140(1):57-68. PubMed ID: 9862403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of buprenorphine, butorphanol and nalbuphine on the initiation of intravenous cocaine self-administration in drug naive mice.
    Kuzmin AV; Gerrits MA; Zvartau EE; van Ree JM
    Eur Neuropsychopharmacol; 2000 Dec; 10(6):447-54. PubMed ID: 11115734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opioid antinociception in ovariectomized monkeys: comparison with antinociception in males and effects of estradiol replacement.
    Negus SS; Mello NK
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1132-40. PubMed ID: 10454487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Age-related differences in sensitivity to the antinociceptive effects of opioids in male rats. Influence of nociceptive intensity and intrinsic efficacy at the mu receptor.
    Smith MA; Gray JD
    Psychopharmacology (Berl); 2001 Aug; 156(4):445-53. PubMed ID: 11498722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antinociception and physical dependence produced by [D-Arg2] dermorphin tetrapeptide analogues and morphine in rats.
    Chaki K; Kawamura S; Kisara K; Sakurada S; Sakurada T; Sasaki Y; Sato T; Susuki K
    Br J Pharmacol; 1988 Sep; 95(1):15-22. PubMed ID: 2905901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats.
    Stinus L; Cador M; Zorrilla EP; Koob GF
    Neuropsychopharmacology; 2005 Jan; 30(1):90-8. PubMed ID: 15138444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relative involvement of spinal opioid receptors in physical dependence on intrathecal butorphanol and morphine.
    Wongchanapai W; Tsang BK; He Z; Ho IK
    Pharmacol Biochem Behav; 1998 Aug; 60(4):899-907. PubMed ID: 9700974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased analgesic potency of mu agonists after continuous naloxone infusion in rats.
    Paronis CA; Holtzman SG
    J Pharmacol Exp Ther; 1991 Nov; 259(2):582-9. PubMed ID: 1658305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of morphine, nalbuphine, and butorphanol on adrenergic function in canine saphenous veins.
    Muldoon S; Otto J; Freas W; Watson RL
    Anesth Analg; 1983 Jan; 62(1):21-8. PubMed ID: 6129820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions.
    Dum JE; Herz A
    Br J Pharmacol; 1981 Nov; 74(3):627-33. PubMed ID: 6271322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A study of the analgesic interaction between intrathecal morphine and subcutaneous nalbuphine in the rat.
    Loomis CW; Penning J; Milne B
    Anesthesiology; 1989 Nov; 71(5):704-10. PubMed ID: 2817464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic co-administration of nalbuphine attenuates the development of opioid dependence.
    Raghav R; Jain R; Dhawan A; Roy TS; Kumar P
    Pharmacol Biochem Behav; 2018 Dec; 175():130-138. PubMed ID: 30312633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.